ProCE Banner Activity

Expert Perspectives on Key New Evidence in CLL Therapy

Clinical Thought
In this commentary, experts share their thoughts on key phase III trials of BTK inhibitors in CLL that were recently presented at ASCO 2021 and EHA 2021.

Released: July 28, 2021

Expiration: July 27, 2022

Share

Faculty

Anthony Mato

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

William G. Wierda

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by the USF Health
ProCE Banner

Supporters

AbbVie Inc.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics an AbbVie Company

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE, has disclosed that he has received funds for research support from AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Johnson & Johnson, Loxo Oncology, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics and has received consulting fees from AbbVie, Acerta/AstraZeneca, Adaptive, Celgene, DTRM BioPharma, Johnson & Johnson, Pharmacyclics, Sunesis, TG Therapeutics, and Verastem.

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

William G. Wierda, MD, PhD, has disclosed that he has received funds for research support from AbbVie, Acerta, Cyclacel, Genentech, Gilead Sciences, Janssen, Juno, Kite, Loxo, miRagen, Novartis, Oncternal, Pharmacyclics, Sunesis, and Xencor.